Technology Opportunities & Ventures
While focus is on header menu items,
press the down arrow to open sub-menu.
press the down arrow to open sub-menu.
Learn more about the drugs and therapies developed at NYU that are currently in or on their way to the market.
| Product | Licensee | Indication |
Preclinical
Phase I
Phase II
Phase III
Approved
|
|---|---|---|---|
| LORBRENA® (lorlatinib) | Pfizer, Inc. | Non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of the body | Progress: 100% |
| Mosquirix™ (RTS,S)* | GSK | Malaria (vaccine) | Progress: 100% |
| ORACEA® (doxycycline, USP) | Galderma | Inflammatory lesions of rosacea | Progress: 100% |
| PROMACTA® (eltrombopag) | GSK | Thrombocytopenia in patients with chronic immune thrombocytopenic purpura that did not get better with other treatment | Progress: 100% |
| REMICADE® (infliximab) | Janssen | Crohn’s disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Plaque psoriasis | Progress: 100% |
| SUTENT® (sunitinib malate) | Pfizer Inc. | Gastrointestinal stromal tumor, Renal cell carcinoma, Pancreatic cancer | Progress: 100% |
| XALKORI® (crizotinib) | Pfizer Inc. | Metastatic non-small cell lung cancer (NSCLC) where tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive | Progress: 100% |
| ZINECARD® (dexrazoxane) | Pfizer Inc. | Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use | Progress: 100% |
| Brexpiprazole | Lundbeck | Agitation in Alzheimer’s Disease | Progress: 80% |
| HyBryte™ | Soligenix | Cutaneous T-cell lymphoma | Progress: 80% |
| Generx | Gene Bio Therapeutics | Refractory angina | Progress: 80% |
| ARGX-119 | argenx | Neuromuscular Indications | Progress: 40% |
| LYT-200 | PureTech | Cancer indications, including: Pancreatic ductal adenocarcinoma, Colorectal cancer, Cholangiocarcinoma | Progress: 40% |
| TBD | Nostrum | Pulmonary fibrosis | Progress: 40% |
| TBD | Empriver | Alzheimer’s disease | Progress: 40% |
| LYT-210 | PureTech | Cancer | Progress: 20% |
| TBD | Janssen | Staph infection | Progress: 20% |
| TBD | Janssen | Oncolytic virus | Progress: 20% |
*Not FDA approved/Not available in the U.S. Mosquirix received a positive scientific opinion from the European Medicines Agency on the proposal for the vaccine to be used to vaccinate children aged 6 weeks to 17 months outside the European Union.